Ultrasound-Guided Beta-Blockers: a new hope for septic shock?

NCT ID NCT07313605

Not yet recruiting Disease control Sponsor: John Basmaji Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether using ultrasound to guide treatment with the beta-blocker esmolol is feasible in patients with septic shock. Septic shock is a life-threatening condition where infection causes very low blood pressure and a dangerously fast heart rate. The trial will enroll 100 adults and compare those receiving esmolol (to slow the heart) against standard care, monitoring for 90 days. The main goal is to see if a larger, definitive trial can be done successfully.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Esmolol (a beta-blocker drug given intravenously to slow heart rate)
What this could lead to: If this pilot succeeds, it could pave the way for a larger trial testing whether beta-blockers guided by ultrasound improve survival in septic shock.
What could go wrong: This is a small, early-phase feasibility study, not designed to prove benefit. Beta-blockers can be harmful if the heart is not well-filled or functioning poorly, and results may not generalize.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPTIC SHOCK

More trials for these conditions

Other studies related to the condition(s) this trial covers.